$2.59
+0.03 (+1.17%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CLRB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
13 interventional · 1 with posted results
Held by 1 tracked-famous manager (Balyasny Asset Management L.P.) · FINRA short interest 3.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluation of Iopofosine I 131 vs. R-CD in WM PatientsNCT07766421Superiority of progression free survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate, Dexamethasone | Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinaemia Refractory, Waldenstrom Macroglobulinemia With Nodal Disease, Waldenstrom's Macroglobulinemia Recurrent | 219 | Jan 2032 | ≤ 1,991 d | 2026-08-14 |
| Phase 1 Study of CLR 125 in Triple Negative Breast CancerNCT07311993Dose Determination for CLR 125Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Iopofosine I 131, CLR 125 | Breast Cancer | 60 | Feb 2028 | ≤ 559 d | 2026-06-03 |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasNCT03478462Number of participants with dose limiting toxicities (DLT)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: CLR 131 | Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma | 30 | 2026-08-25 | in 6 d | 2026-03-18 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromNCT02952508Part A [CLOVER-1] Clinical benefit rateNon-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose | Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma | 120 | 2026-06-22 | — | 2026-03-18 |
| Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGNCT05610891Safety Evaluation of CLR 131Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: CLR 131 | High-Grade Glioma | 50 | May 2026 | — | 2026-03-18 |
| Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaNCT02278315Number of participants with dose limiting toxicities (DLT)Open-label · Treatment | Phase 1 | Completed | Drug: I-131-CLR1404, dexamethasone, I-131-CLR1404 | Multiple Myeloma | 31 | 2020-12-09actual | — | 2023-02-22 |
| Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent GlioblastomaNCT01898273Optimal Imaging Parameters - DoseOpen-label · Diagnostic | Phase 2 | Terminated | Drug: I-124-CLR1404 | Glioblastoma | 7 | Sep 2015 | — | 2015-09-09 |
| Open-Label Study of I-131-CLR1404 in Subjects With Recurrent GliomaNCT01778088Evaluate the 6-month survival rate of subjects receiving I-131-CLR1404 for relapsed gliomaOpen-label · Treatment | Phase 2 | Withdrawn | Drug: I-131-CLR1404 Injection | Glioma | 0 | Jun 2014 | — | 2014-02-25 |
| Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has ReturnedNCT01495663Determination of the recommended dose of I-131-CLR1404 in treating subjects with relapsed or refractory advanced solid malignanciesOpen-label · Treatment | Phase 1 | Completed | Drug: I-131-CLR1404 | Cancer | 12 | Nov 2013actual | — | 2015-02-26 |
| A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard TherapyNCT01058512To evaluate changes in viral loadOpen-label · Treatment | Phase 2 | Completed | Drug: NOV-205 | Hepatitis C | 22 | Dec 2010actual | — | 2022-07-25 |
| Study of NOV-002 in Combination With Chemotherapy to Treat Lung CancerNCT00347412Overall survival during the length of the trial, length of the trial is approximately two years after last patient inRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Paclitaxel, NOV-002, Carboplatin | Non Small Cell Lung Cancer | 903 | Jan 2010actual | — | 2022-07-25 |
| Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian CancerNCT00345540results2015-03-10Response RateOpen-label · Treatment | Phase 2 | Completed | Drug: NOV-002, Carboplatin | Ovarian Cancer | 15 | May 2008actual | — | 2015-03-10 |
| Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard TherapyNCT00372983To evaluate the pharmacokinetic profile of different dosing regimens of NOV-205.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: NOV-205 | Hepatitis C | 30 | — | — | 2007-12-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19